Industry news

Small drug companies grow as big pharma outsources

Julia Bradshaw / The Telegraph

The UK’s small, privately-owned pharmaceutical companies often go under the radar, but they’re playing an increasingly important role in Britain’s healthcare sector and posting impressive growth rates, according to a report from consultants Catalyst Corporate Finance.

FDA issues draft guidances on drug, device labeling

Amirah Al Idrus / Fierce Biotech

The FDA released a pair of draft guidances detailing its recommendations on how drug and device makers should communicate information about their products on their labeling and to payers.

Donald Trump’s first 100 days, and beyond, for biopharma

Ben Adams / Fierce Biotech

As Donald Trump is sworn into office today, we look at what the next 100 days and indeed the next four years could mean for the biopharma industry through his recent candidates for the top healthcare roles, his policies (which are still coming into focus), and the power that 140 characters can have.

Pfizer joins Big Pharma peers in R&D matchmaking program

Nick Paul Taylor / FierceBiotech

Pfizer has become the latest Big Pharma company to join a consortium that matches drugmakers to researchers in Cambridge, U.K. The consortium pairs Pfizer, AstraZeneca, GlaxoSmithKline and its other members to academic researchers to facilitate the transfer of assets and funds between the two groups.

23 January 2017

Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business overview to outline the clinical status of its CNS-selective GABA_A modulator, ganaxolone, and an overview of near-term value-creating milestones expected in 2017. 

Pharma CEOs in Davos put brave face on Trump presidency

Ben Hirschler / Reuters

Leaders of the global pharmaceutical industry, blasted by incoming U.S. President Donald Trump for "getting away with murder" on drug prices, are putting a brave face on the challenges in their biggest market.

FDA has a backlog of 1,000 foreign plants that have never been inspected despite progress, GAO report finds

Eric Palmer / Fierce Pharma

The FDA in the last eight years has nearly doubled the number of annual foreign plant inspections it conducts, with India and China seeing the largest numbers of inspectors. But the agency still has a huge backlog of foreign plants that have never been seen and is struggling to fill foreign office jobs.  

U.K.’s path to ‘hard Brexit’ raises worries, cautious optimism

Nick Paul Taylor / FierceBiotech

The UK BioIndustry Association (BIA) has responded with cautious optimism and concerns to the British prime minister’s clearest statement yet on the priorities for Brexit negotiations. Theresa May drew praise for talking up the importance of science and cross-border collaboration to post-Brexit Britain, but is yet to provide clarity on key points including immigration and regulation.

PhRMA to apply big bucks to new theme in 2017 marketing campaign

Beth Snyder Bulik / FiercePharmaMarketing

Pharma industry group PhRMA is gearing up for a new marketing campaign to replace its current “From Hope to Cures” push, with a new theme and tagline set to debut this month. The multiyear campaign promises spending in the “tens of millions” each year to drum up support for the reputationally challenged pharma industry.

Where the money is, Part Two: The top cities and regions for biotech VC investments

John Carroll / Endpoints News

Make no mistake about it. Despite another big showing for the Bay Area in the roster of VC deals that delivered in 2016, Cambridge/Boston was the clear leader in the US last year, according to the latest tally of 2016 numbers by Thomson Reuters.